Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si
October 5, 2016 4:35 PM EDTResults from ORION-1 interim analysis with Day 90 follow-up will be presented in Late-Breaking Clinical Trial Session at American Heart Association (AHA) meeting on November 15, 2016
The Company anticipates that top-line data from Day 180 follow-up for up to 200 patients will also be presented at the Late-Breaking Clinical Trial Session
Based on review of safety data by the Independent Data Monitoring Committee through August 26, 2016 (unblinded) and the Company through September 29, 2016 (blinded), no material safety issue and, in particular, no drug-related neuropathy, elevation of liver enzymes or changes in renal function, has been... More
